CheckOrphan Advisory Board
Hans-Peter Beck, PhD
Research Group Leader, Swiss Tropical Institute
Hans-Peter Beck is a research group leader at the Swiss Tropical Institute and is Professor for Molecular Parasitology at the University of Basel. His research is on tropical diseases mainly focusing on malaria. The group of Dr. Beck conducts molecular-epidemiological research thus bringing laboratory based research into applications in the field in malaria endemic areas. This also includes molecular monitoring of clinical trials in endemic areas. A second focus of research has always been basic molecular and cellular biology in malaria. Dr. Beck’s research group studies the required interactions of proteins responsible for parasite’s survival. Further information about research projects can be found at the Molecular Parasitology Group's webpage.
Dr. Beck received his PhD in Cell biology at the University of Tübingen, Germany and conducted his post-doctoral research at the Wellcome Centre of Molecular Parasitology in Glasgow, UK. He then moved as senior researcher to the Papua New Guinea Institute of Medical Research in Madang, Papua New Guinea, where he conducted molecular epidemiological studies and participated in a malaria vaccine trial, where he monitored the parasite dynamics. After several years, Dr. Beck returned to Germany, working as Senior Research Fellow at the Institute for Cell Biology at the University of Witten-Herdecke where he also submitted successfully his habilitation. He joined 1995 the Swiss Tropical Institute, Basel, Switzerland, as head of Molecular Parasitology-Epidemiology and where he became Professor for Molecular Parasitology in 2004.
All research of Dr. Beck, basic and applied, has been guided by the thorough believe that progress in the fight against diseases, particular those highly complex diseases such as malaria can only be made by a complete understanding of the underlying cell biology and molecular events underlying the biology. Therefore, the research group of Dr. Beck is actively involved in research capacity building and training of individuals from resource poor countries.
Brian Duckworth, JD
Founder, Duckworth Law Firm
Brian Duckworth is the Founder and Principal of the Duckworth Law Firm, a firm that specializes in diversity, global business development, and contract law. He serves as Chief Legal Counsel and consulting specialist to the Systems Management Institute. Experienced in mergers and start-ups, Mr. Duckworth was Chairman & C.E.O. of one of California's largest nonprofit housing corporations which has constructed thousands of units. Mr. Duckworth represents clients both nationally and internationally in areas involving contracts, global business relations, and business development. Fluent in Chinese, he has led business teams to China and Mongolia where he successfully negotiated joint ventures, contracts, and business agreements in aircraft development and highway construction with both government agencies and private enterprises. Earlier in his legal career, he has practiced Employment Law, Municipal Law, Construction Law, and Property Law. Mr. Duckworth has successfully won judgments or settlements against such corporations and agencies as I.B.M., Seagate Technologies, Terryon Corporation, and Santa Clara County. Believing that the future is today, and championing the power of consulting, coaching, and influence, Mr. Duckworth is committed to building business opportunities around the world and has personally funded scholarships to educate students in China. Also, understanding the power of personal commitment, Mr. Duckworth has served as primary director of educational programs at the high school level, and an instructor of Chinese Language at the college level. Licensed to teach courses in Law, he has lectured in legal procedures and government. He is a member of the California Bar Association and practices in the state of California.
David Galipeau, MBA
Chief, Web Unit at United Nations
David Galipeau completed his B.A. in economics and finance at Sir Wilfrid Laurier University in Canada. After graduation, he worked in the international financial markets trading commodities. He then travelled to Europe and for 10 years was employed within the Pharmaceutical/Consumer Goods industries as marketing/sales and business development manager for Germany, Greece, Turkey and the eastern European countries. In 1994, he completed his MBA at Clemson University, South Carolina and started post-graduate research in Social Informatics/Cognitive Psychology. His early research, funded by the European Commission Framework IV, focused on the social impact of ICTs (Information and Communications Technology), specifically internet technologies and online communications. He is concentrating on global and local youth movements and the use of new media/technologies to enhance advocacy, reduce poverty and increase economic empowerment. During 2002
Roger L. Kaspar, PhD
CEO and Founder, TransDerm
Roger L. Kaspar, Ph.D, is the CEO and scientific founder of TransDerm, a company focused on developing novel therapeutics, including inhibitors based on RNA interference (RNAi) technology, for skin disorders.Dr. Kaspar received his doctorate from the University of Washington (Seattle) in biochemistry (David Morris) and performed post-doctoral work at M.I.T. (Lee Gehrke), Stanford University (Helen Blau), and Chiba University (Tomohito Kakegawa). After serving on the faculty at Brigham Young University (Utah) in the Department of Chemistry and Biochemistry, he left academia to work at SomaGenics, prior to founding TransDerm. Drawing on his expertise is in the area of post-transcriptional gene regulation, his current efforts are focused on designing highly potent and selective therapeutic siRNAs that target disease-causing genes in skin disorders, including pachyonychia congenita, and investigating methods to efficiently deliver agents such as siRNAs to appropriate skin cells.
Marten Tendelenburg, MD
Senior Consultant of Internal Medicine, Universty Hospital Basel
Dr. Marten Trendelenburg is currently senior consultant for Internal Medicine and leads the Clinical Immunology Laboratory at the University Hospital, Basel. As a physician, he brings with him a deep concern for the well-being of his patients. That is why he also combines his patient consultations with extensive research efforts. He has currently published 22 peer-reviewed research studies and 26 non-peer reviewed studies on topics such as: autoimmune diseases, biomarkers, transplantations and steroid compounds. A large focus of his research surrounds a Molecule known as C1q and the role it plays in patients with the rare disease, Systemic Lupus Erythematosus. Due to his vast experience with Systemic Lupus Erythematosus, he has become a renowned specialist for people with this rare disease. Dr. Trendelenburg started his medical studies at the University of Saarland in Homburg, Germany. During his medical studies, he also pursued internships at the University of Lausanne, Guy's Hospital in London, the Royal Brompton National Heart Hospital in London, the University Hospital Basel and the Cantonal Hospital in Chur/CH. After passing the German Medical Board exam on May 5, 1995, he pursued his first specialization in internal medicine at the University Clinic of Mannheim, Germany. From 1997 until 2001, Dr. Trendelenburg performed rotations as an assistant physician and worked in the immunonephrology laboratory at the University Hospital, Basel. Then in October 2001, he served as a Clinical Research Fellow in the department of Rheumatology at Hammersmith Hospital, Imperial College, London. After two years work in London, Dr. Trendelenburg returned to the University Hospital, Basel where he currently practices and received a second specialization in immunology (consultant immunologist). Outside of the hospital, Dr. Trendelenburg serves as an Expert Referee for the Swiss National Foundation and for the following scientific journals: Annals of Rheumatic Diseases, Lupus, Clinical Experimental Immunology, Immunology, Journal of Thrombosis and Haemastasis, Journal of Infectious Diseases, Scandinavian Journal of Rheumatology, Rheumatology and Current Medicinal Chemistry. In addition, he pioneered the development and marketing of an anti-C1q test for B